BioLineRX Ltd. · TASE:BLRX
BioLineRX — Investor Presentation (December 2017)
41 slides from BioLineRX's investor presentation, Dec 5, 2017

Slide 1: Transforming science into medicine
Transforming science into medicine

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements.” These statements include words like “may,” “expects,” “believes,” “plans,” “scheduled,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and u

Slide 3: Corporate presentation
Corporate presentation BIOUING

Slide 4: Attractive investment case
Attractive investment caseStrong balance sheet$55 million (end Q3 2017)Significant upcoming milestones:Top line combination results from phase 2 COMBAT study in pancreatic cancerResults from initial lead-in period of phase 3 GENESIS study in SCMInterim analysis from phase 2b BLAST study in consolida

Slide 5: Main pipeline assets
Main pipeline assets 5 PROJECT INDICATION REGULATORY APPROVAL PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 Stem-cell mobilization Consolidation AML Solid tumors CANCER BL-8040 AGI-134 Type 1 diabetes immunology BL-9020 Skin lesions other BL-5010 Maintenance AML Gastric cancer Non-small cell lung cancer Panc

Slide 6: 2017 achievements
2017 achievements BIOUING

Slide 7: Main Achievements in 2017
Main Achievements in 2017 Completed recruitment for phase 2a COMBAT study in pancreatic cancer (Merck collaboration) 3 phase 1b/2 studies initiated under the Genentech collaboration (pancreatic, gastric and AML)Reached understandings with FDA on phase 3 registrational study in autologous SCMAcquired

Slide 8: Clinical update on BL-8040 platform
Clinical update onBL-8040 platform

Slide 9: BL-8040 Clinical Program
WS BL-8040 Clinical Program REGULATORY PROJECT INDICATION Croner | | roc _— _ _ a isles ‘CANCER al-g040 stem-cell mobilization CC ———*D Consolidation AML eqD Maintenance AML EEE Gastric cancer ~zD Gone Non-smal cll lng cancer | Pancreatic cancer A, —— Pancreatic cancer a —____ € sp BIOLINE™><

Slide 10: BL-8040 for Stem-cell Mobilization
BL-8040 for Stem-cell Mobilization

Slide 11: Stem cell mobilization - Indications
Stem cell mobilization - Indications 11 Stem cell mobilization Autologous Haploidentical Allogeneic Phase 3 study- GENESIS: One dose of BL-8040 on top of G-CSF Phase 2 study to assess the effect of BL-8040 as a single agent for Allo and Haplo transplant Phase 1 study in Healthy volunteers of BL-8040

Slide 12: GENESIS Phase 3 - Mobilization of SC in Multiple Myeloma patients
GENESIS Phase 3 - Mobilization of SC for autologous transplant in Multiple Myeloma patients 12 G-CSF, granulocyte-colony stimulating factorClinicaltrials.gov. NCT0346529 Study designPart 1: Lead in period - dose confirmation in up to 30 Multiple Myeloma patientsPart 2: Randomized placebo controlled

Slide 13: GENESIS Study: Objectives
GENESIS Study: Phase 3 SCM in Multiple Myeloma patients 13 Objectives To demonstrate that the combination of BL-8040 + G-CSF is superior to G-CSF alone in… Primary The ability of mobilize > 6M CD34+ cells in up to 2 apheresis Secondary The ability to mobilize > 2M CD34+ cells in 1 apheresis Safety a

Slide 14: BL-8040 – Solid Tumors
BL-8040 – Solid TumorsMobilizing and promoting infiltration of immune cells and reducing immunosuppression in the tumor microenvironment

Slide 15: BL-8040 - Addressing unmet needs in cancer immunotherapy
BL-8040 - Addressing unmet needs in cancer immunotherapy Despite significant advances in cancer immunotherapy, material needs remain:Improving the efficacy of immunotherapy in “cold” tumors, such as pancreatic cancerIncreasing rates and durability of response to existing therapies such as anti-PD1 a

Slide 16: COMBAT study: Advanced Pancreatic Cancer
COMBAT study: Advanced Pancreatic Cancer A Phase 2a, multi-center, open-label study to assess the safety and efficacy of BL-8040 in combination with Pembrolizumab (Keytruda) in patients with advanced pancreatic cancer 16 Phase 2a open-label study in combination with Pembrolizumab (n=30): NCT02826484

Slide 17: COMBAT - Objectives
COMBAT-Objectives 17 Objectives To demonstrate that the combination of BL-8040 and Pembrolizumab… Primary Induces responses assessed as overall response (CR+PR) Secondary Prolongs the progression free survival (PFS) Prolongs the overall survival (OS) Safety and Tolerability Is safe and tolerable Oth

Slide 18: Participating Sites and PIs
Participating Sites and PIs Site City/Country PI Patients enrolled Beth Israel Deaconess MC Boston/US Manuel Hidalgo – study PI- 6 Rambam MC Haifa/Israel Ron Epelbaum 5 Tel Aviv Sourasky MC Tel Aviv/ Israel Ravit Geva 4 Sheba MC Ramat Gan/ Israel Talia Golan 4 Rabin MC Petach Tikva/Israel Solomon Sh

Slide 19: BL-8040 for Acute Myeloid Leukemia
BL-8040 for Acute Myeloid Leukemia

Slide 20: Acute Myeloid Leukemia - Treatment Lines
Acute Myeloid leukemia-Treatment Lines 20

Slide 21: Study BL-8040.01: Encouraging results in relapsed/refractory AML
Study BL-8040.01: Encouraging results in patients with relapsed/refractory AML 21 CR, complete response; CRi, complete response with incomplete hematological recovery; AML, Acute Myeloid Leukemia Study designDose escalation (0.5 to 2.0 mg/kg) with expansion cohort at 1.5mg/kg Phase 1/2a dose escalat

Slide 22: BL-8040.01 for Relapse/Refractory AML - Key Findings
BL-8040.01 for Relapse/Refractory AML-Key Findings 22 Population Relapsed or refractory AML patients including patients after allogeneic transplantation Primary Endpoint Safety and Tolerability BL-8040 was found to be safe and well tolerated in combination with high dose cytarabine Secondary endpoin

Slide 23: BL-8040.01 - Overall Survival in R/R AML patients
BL-8040.01- Overall Survival in R/R AML patients treated with BL-8040 +HiDAC 23

Slide 24: BLAST study: Consolidation therapy in AML
BLAST study: Consolidation therapy in AML patients in first remission Treatment: Two or three cycles (age-based) of consolidation with high-dose Ara-C together in combination with either BL-8040 or placebo 24 BL-8040 potentially offers AML patients prolonged remission and increased overall survival

Slide 25: BLAST - Objectives
BLAST-Objectives 25 Objectives To demonstrate that the combination of BL-8040 High Dose Cytarabine (HiDAC) Primary Prolongs the Relapse free survival Secondary Reduces the minimal residual disease (MRD) Prolongs the Overall survival Safety and Tolerability Is safe and tolerable.

Slide 26: BATTLE study – BL-8040 and Atezolizumab in AML
BATTLE study – Combination of BL-8040 and Atezolizumab in AML patients at a high risk of relapse A Phase 1b/2, multi-center, single arm, open-label study, to evaluate the safety and efficacy of BL-8040 in combination with Atezolizumab for maintenance treatment in AML patients of 60 years or older th

Slide 27: BATTLE - Objectives
BATTLE-Objectives 27 Objectives To demonstrate that the combination of BL-8040 and Atezolizumab… Primary Prolongs the relapse free survival (RFS) time as compared to historical data. Secondary Reduces the minimal residual disease (MRD) Prolongs the Overall Survival (OS) time as compared to historica

Slide 28: AGI-134: a novel immuno-oncology agent
AGI-134: a novel and unique immuno-oncology agent tackling the challenge of tumor neoantigen heterogeneity

Slide 29: AGI-134 – Harnessing pre-existing immunity
AGI-134 – Harnessing pre-existing immunity to deliver a patient-specific anti-tumor response 29 Tumors vary from patient to patient in their neoantigen load and identityAGI-134 is a universal drug that evokes a vaccine effect via a unique, hyperacute, multi-arm mechanism that targets patient-specifi

Slide 30: alpha-Gal and anti-Gal
alpha-Gal and anti-Gal 30 The alpha-Gal epitope is abundantly synthesized on glycolipids of non-primatesDue to constant exposure to this antigen (expressed by gut flora) humans develop and maintain high levels of anti-Gal Abs Xenotransplantation experiments in the 1980s-90s found that, when introduc

Slide 31: AGI-134 synthetic a-Gal glycolipid molecule
AGI-134 A fully synthetic a-Gal glycolipid molecule for intratumoral injection into solid tumors, to induce an immune response against a patient’s own neoantigens a-Gal linker phospholipid 31

Slide 32: AGI-134 – Mechanism of Action
AGI-134 – Mechanism of Action 32

Slide 33: Compelling Pre-Clinical Data Supports Phase I Study
Compelling Pre-Clinical Data Supports Phase I Study due 1H 2018 A single dose of AGI-134 into a primary tumor protected mice from secondary tumor development for more than 90 days Combination of AGI-134 with an immune checkpoint inhibitor (anti-PD-1) resulted in increased efficacy over either agent’

Slide 34: How is AGI-134 differentiated from competitors?
How is AGI-134 differentiated from competitors? Evokes personalized anti-tumor immunity Targets a multitude of patient-specific neoantigens Does not require complex ex vivo processing or computer modelling Harnesses pre-existing antibodies Directly labels the treated tumor for

Slide 35: High level outline of Phase 1/2a clinical study
High level outline of Phase 1/2a clinical study RP2D = Recommended Phase 2 Dose Study completion Accelerated escalation monotherapy Monotherapy Basket Part I Part II Combination – HNSCC RP2D Combination – mCRC Combination – STS AGI-134 AGI-134+ IO 35 mCRC = Metastatic Colorectal Cancer STS = Soft Ti

Slide 36: AGI-134 – Immune monitoring strategy
Treated and distal tumors:Level and composition of immune infiltrate & change with treatmentChanges in infiltrating T cell repertoire Changes in inflammatory signature Peripheral blood:Anti-Gal antibody titer and change with treatmentChanges in circulating T cell repertoireChanges in pro-inflammator

Slide 37: Looking ahead
Looking ahead BIOUING

Slide 38: Principal Milestones for 2017/2018
2017 2018 Principal Milestones for 2017/2018 38 BL-8040 (Allo SCM)Phase 2 partial results BL-8040 (Auto SCM)Lead-in results BL-8040 (Panc., Gastric, AML) Phase 1/2 initiation (Genentech) BL-8040 (pancreatic) Phase 2 initiation (MDACC) AGI-134Agalimmune acquisition BL-8040 (Allo SCM)Phase 2 top-line

Slide 39: Looking into the upcoming year
Looking into the upcoming year Multiple read-outs during 2018: COMBAT top line results , Phase 3 lead-in results and potential BLAST interim resultsContinue to lay foundations for future events: Phase 3 in SCM, AGI-134 initiation Company expecting to meet previously-stated timelinesExpecting continu

Slide 40: Long-term vision
Long-term vision BIOUING

Slide 41: BioLineRx in Five Years
BioLineRx in Five Years Our plan is to become a significant player in the biotech industryWith critical mass of advanced projects in developmentAlongside portfolio of revenue-generating assetsWe intend to achieve the following:2-3 products in the market, with material amount of sustainable revenuesP
Source: SEC EDGAR · 6-K filed Dec 5, 2017
More decks from BioLineRX Ltd.
Investor Presentation (July 2026)39 slides · July 2026
Q1 2026 Earnings Presentation28 slides · May 27, 2026
Technical Presentation (December 2020)14 slides · Dec 16, 2020
Technical Presentation (December 2020)49 slides · Dec 16, 2020
Investor Presentation (February 2019)31 slides · Feb 4, 2019
Investor Presentation (October 2018)30 slides · Oct 1, 2018